Jole Ventriglia

Naples, 80131, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology Network.

Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology Network.

Journal: Current oncology (Toronto, Ont.)

Published: April 22, 2026

Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC).

Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC).

Journal: BMC cancer

Published: January 20, 2026

KELIM score: A marker of chemosensitivity in ovarian cancer.

KELIM score: A marker of chemosensitivity in ovarian cancer.

Journal: Cancer treatment reviews

Published: October 27, 2025

The immunotherapy era in ovarian clear cell carcinoma: current evidence and future perspective.

The immunotherapy era in ovarian clear cell carcinoma: current evidence and future perspective.

Journal: Frontiers in immunology

Published: July 07, 2025

The emerging role of PARP inhibitors in prostate cancer: A narrative review.

The emerging role of PARP inhibitors in prostate cancer: A narrative review.

Journal: Cancer treatment reviews

Published: June 16, 2025

Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE/MITO 42 study, a retrospective analysis of italian MITO centers.

Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE/MITO 42 study, a retrospective analysis of italian MITO centers.

Journal: Frontiers in oncology

Published: June 05, 2025

Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial.

Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial.

Journal: ESMO open

Published: September 11, 2024

Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type.

Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type.

Journal: Frontiers in oncology

Published: April 05, 2024

Endometrial cancer in the elderly: Characteristics, prognostic and risk factors, and treatment options.

Endometrial cancer in the elderly: Characteristics, prognostic and risk factors, and treatment options.

Journal: Critical reviews in oncology/hematology

Published: March 25, 2024

Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report.

Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report.

Journal: Frontiers in immunology

Published: September 28, 2023

Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors.

Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: February 09, 2023

The role of immunotherapy treatment in non-clear cell renal cell carcinoma: An analysis of the literature.

The role of immunotherapy treatment in non-clear cell renal cell carcinoma: An analysis of the literature.

Journal: Critical reviews in oncology/hematology

Published: January 12, 2023

Showing 1-12 of 36

Last Updated: 09/26/2026